3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
25
Leukemia, Myeloid, Chronic-Phase
14
Leukemia
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Recurrence
4
Breast Neoplasms
4
Blast Crisis
4
Prostatic Neoplasms
3
Neoplasms
3
Bronchiolitis Obliterans Syndrome
3
Neoplasm Metastasis
2
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid, Accelerated Phase
2
Advanced Breast Cancer
2
Philadelphia Chromosome
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Indications Cancer
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Cancer
1
Interventions
Nivolumab
19
Ipilimumab
9
linrodostat
6
relatlimab
4
Pemetrexed
4
Paclitaxel
4
Carboplatin
4
ARRY-334543
4
Docetaxel
3
regorafenib
2
anlotinib
2
abemaciclib
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Gemcitabine
2
Cyclophosphamide
2
Capecitabine
2
6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline
2
vorolanib
1
trametinib
1
tislelizumab
1
sargramostim
1
ralimetinib
1
prexasertib
1
palifosfamide lysine
1
p38 Mitogen-Activated Protein Kinases
1
mirdametinib
1
lirilumab
1
indibulin
1
gedatolisib
1
fluzoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Cancer
×
Dasatinib
×
Clear all
NCT02750514
2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2
Terminated
295 enrolled
21 charts